🇺🇸 FDA
Patent

US 7652035

CRF receptor antagonists and methods relating thereto

granted A61PA61P1/00A61P25/00

Quick answer

US patent 7652035 (CRF receptor antagonists and methods relating thereto) held by Neurocrine Biosciences, Inc. expires Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Jan 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61P, A61P1/00, A61P25/00, A61P25/18, A61P25/22